Research programme: siRNA therapeutics - siRNAsense

Drug Profile

Research programme: siRNA therapeutics - siRNAsense

Alternative Names: siRNA targeting tissue factor

Latest Information Update: 27 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator siRNAsense
  • Developer Polyplus-transfection; siRNAsense
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Cancer metastases; Prostate cancer

Highest Development Phases

  • Discontinued Cancer; Malignant melanoma; Neurological disorders; Prostate cancer

Most Recent Events

  • 27 Oct 2016 Discontinued - Preclinical for Cancer, Malignant melanoma, Neurological disorders and Prostate cancer in Norway as information for the products is unavailable on the company pipeline (siRNAsense pipeline, October 2016)
  • 09 Oct 2013 No development reported - Preclinical for Cancer in Norway (unspecified route)
  • 09 Oct 2013 No development reported - Preclinical for Malignant melanoma in Norway (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top